Accueil   Diary - News   All news Adocia announces positive Phase 1b results

Adocia announces positive Phase 1b results

Adocia announces positive Phase 1b results on the post-meal effect of BioChaperone® Combo in patients with type 1 and type 2 diabetes

 

Adocia announced positive topline results from a Phase Ib randomized double-blind crossover trial of BioChaperone Combo in 28 subjects with type 1 diabetes. The study, comparing the effect on post-meal glycemic control of individualized doses of BioChaperone Combo and Humalog® Mix75/25™ (Eli Lilly) injected at the beginning of standardized meals, met its primary endpoint, demonstrating superiority of BioChaperone Combo in the reduction of post-meal blood glucose over the first two hours (Delta-AUC-BG(0-2h)) compared to Humalog® Mix75/25™.

 

 Read the press release 1

 

 

Adocia announced positive topline results from a Phase 1b randomized double-blind crossover trial of BioChaperone Combo in 24 subjects with type 2 diabetes under euglycemic clamp. The study was designed to compare the pharmacodynamic profile of BioChaperone Combo (single dose of 0.8 U/kg) to that of Humalog Mix75/25 (Eli Lilly, single dose of 0.8 U/kg) and of the separate and simultaneous injections of Lantus (insulin glargine, Sanofi, single dose of 0.6 U/kg) and Humalog (insulin lispro, Eli Lilly, single dose of 0.2 U/kg). The two key parameters for this comparison were the early prandial effect (AUCGIR(0-2h)) and the late basal effect (AUCGIR(24-30h)) of the three treatments. Based on these two parameters, BioChaperone Combo was found to be significantly superior to Humalog Mix75/25 and exhibited no difference compared to the separate injections of Lantus and Humalog.

 

Read the press release 2